Evaluation of Treatment of Ear Lobe Keloid with Triamcinolone Injection and Surgical Excision

Title: Evaluation of Treatment of Ear Lobe Keloid with Triamcinolone Injection and Surgical Excision

Authors: K. Aravinda Sagar, Kongara Rajesh, Amarendra Prasad N

DOI: http://dx.doi.org/10.18535/jmscr/v4i2.28

Abstract

References

Corresponding Author

Abstract

The study includes 42 consecutive patients with 68 ear lobe keloids. Patients underwent local infiltration of triamcinolone acetonide (TCN) at concentrations of 40mg/ml (Group 1) and 20 mg/ml (Group 2). Different volume of TCN infiltrate according to the size of the lesion. Treatment consisted of three monthly injections before surgery, excision of keloid in the fourth month and perioperative infiltration, followed by two more infiltration of TCN within two months. Post-treatment follow-up of patients was done for12 months.

RESULTS:TCN at concentrations of 20mg/ml and 40mg/ml were effective for the treatment of keloids along with surgical excision,no difference between the groups (p = 0.73).

CONCLUSION:The combination of infiltration of TCN monthly (1.2mg to 2.0mg per mm³ ) and surgical excision is effective for treatment of ear lobe keloid .

KEY WORDS:Keloid; Triamcinolone Acetonide; Wound Healing; Surgical excision; Recurrence.

References

1. F. Charles Brunicardi,Dans K. Anderson, Timothy R. Billar,David L.Dunn, John G. Hunter, Jeffrey B.Mathews,Raphael E. Pollock: Schwartz’s principles of surgery: tenth edition:ch.9,wound healing, pg 261-64.

2. M. Townsend,Jr., R.Daniel Beauchamp, B.Mark Evers, Kenneth L. Mattox: Sabiston Textbook of surgery: The Biological Basis of Modern Surgical Practice, 19^th edition, ch.7,wound healing, pg 164-66.

3. Urioste SS, Arndt KA, Dover JS. Keloidalscars and hypertrophic scars: review and treatment strategies. SeminCutan Med Surg.1999;18(2):159-71.

4. De Felice B, Ciarmiello LF, Mondola P, Damiano S, Seru R, Argenziano C, et al. Differential p63 and p53 expression in human keloid fibroblast and hypertrophic scar fibroblasts. DNA Cell Biol.2007;26(8):541-7.

5. Bettinger DA, Yager DR, Diegelmann RF, Cohen IK. The effect of TGF-beta on keloid fibroblast proliferation and collagen synthesis. PlastReconstr Surg. 1996;98 (5):827-33.

6. Ketchum LD, Robinson DW, Masters FW. Follow-up on treatment of hypertrophic scars and keloids with triamcinolone. PlastReconstr Surg.1971;48(3):256-9.

7. Babin RW, Ceilley RI. The freeze-injection method of hypertrophic scar and keloid reduction. Otolaryngol Head Neck Surg. 1979;87(6):911-4..

8. Shepherd JP, DawberRP.The response of keloid scars to cryosurgery.Plastic Reconstr Surg.1982;70(6):677-82.

9. Botwood N, Lewanski C, LowdellC. The risks of treating keloids with radiotherapy.Br J Radiol.1990;72(864):1222-4.

10. DarziMA,Chowdri NA, Kaul SK, Khan M. Evolution of various methods of treating keloids and hypertrophic scars: a 10-year follow-up study. Br J Plast Surg. 1992;45(5):374-9.

11. Abergel RP, Meeker CA, Oikarinen H, Oikarinen AI, Uitto J. Retinoid modulation of connective tissue metabolism in keloid fibroblast cultures. Arch Dermatol. 1985; 121(5):632-5.

12. Shaffer JJ, TaylorSC, Cook-Bolden F. Keloidal scars: a review with a critical look at therapeutic options. J Am Acad Dermatol.2002;46(2 Suppl Understanding): S63-97.

13. Griffith BH, Monroe CW, McKinney P.A follow-up study on the treatment of keloids with triamcinolone acetonide. Plast Reconstr Surg. 1970;46(2):145-50.

14. Patterson DL, Yunginger JW, Dunn WF, Jones RT, Hunt LW. Anaphylaxis induced by carboxymethylcellulose component of injectable triamcinolone. Ann Allergy Asthma Immunol.1995;74(2):163-6.

15. TuanTL, NichterLS.The molecular basis of keloid an hypertrophic scar formation. Mol Med Today.1998;4(1):19-24.

16. Kim WJ. Cellular signaling in tissue regeneration. Yonsei Med J. 2000;41 (6):692-703.

17. Lee TY, Chin GS, Kim WJ, Chau D, Gittes GK, Longaker MT. Expression of transforming growth factor beta 1, 2, and 3 proteins in keloids. Ann Plast Surg. 1999;43(2):179-84.

Call For Paper Volume 12 Issue 10 November 2024

The JMSCR is accepting manuscripts for its coming issues to be Publish Volume 12 Issue 11 November 2024 the JMSCR invites authors to submit manuscripts Reporting original medical research, original article, research article, case report, systematic reviews, or educational Innovations for publication for the coming issues that will be released in Volume 12 Issue 11 November 2024. Types of manuscripts suitable for JMSCR include: Medical research, Clinical research Educational Innovation, Brief Report, Reviews on Teaching In keeping with high quality scholarship, Read More.....

https://jmscr.igmpublication.org/ems/index.php/jmscr/about/submissions

If any difficulty you can also submit to: This email address is being protected from spambots. You need JavaScript enabled to view it.

JMSCR Menu

Impact Factor SJIF 2024: 7.892

https://sjifactor.com/passport.php?id=1725

Crossref - DOI

Crossref - DOI Prefix: 10.18535/jmscr

Editorial Policy

Authors should prepare their manuscripts according to the instructions given in the authors' guidelines. Manuscripts which do not ..

Frequency of Publication

JMSCR is published as monthly journal with 12 issues per year. Special editions are also planned subjected to the scope and need....

Submission of Articles

Authors are invited to submit their research articles, review papers, Case Report properly formatted as per the author guidelines.........

Search

Abstract